Landos Biopharma, Inc.

LABP · NASDAQ
Analyze with AI
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating Activities
Net Income-$21,935-$39,276-$38,422-$30,144
Dep. & Amort.$44$577$196$137
Deferred Tax$2,129$0$0$293
Stock-Based Comp.$971$1,971$4,118$833
Change in WC$443-$10,074$5,891$5,871
Other Non-Cash-$2,129$1,031$1,156$48
Operating Cash Flow-$20,477-$45,771-$27,061-$22,962
Investing Activities
PP&E Inv.$0-$7-$440-$181
Net Acquisitions$0$236-$235$88
Inv. Purchases$0-$3,671-$174,853-$21,718
Inv. Sales/Matur.$7,775$77,502$116,587$36,030
Other Inv. Act.-$57$0$235-$88
Investing Cash Flow$7,775$74,060-$58,706$14,131
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$16,567$0$93,000$1,518
Stock Repurch.-$3,000$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.$13,567$0$91,607$1,518
Financing Cash Flow$13,567$0$91,607$1,518
Forex Effect$44$46$49-$79
Net Chg. in Cash$909$28,335$5,889-$7,392
Supplemental Information
Beg. Cash$36,640$8,305$2,416$9,808
End Cash$37,549$36,640$8,305$2,416
Free Cash Flow-$20,477-$45,778-$27,501-$23,143